11 promising selected startups delivered their pitch to present their company to interesting partners and discuss their business strategy, technology direction and capital-raising plan. On stage of the 2025 edition of the Dutch Life Sciences conference, Karen Malone, CEO of Sherwood Pharmaceuticals became the proud winner of the Investors Forum and was awarded a partnering ticket with a total value of €2,500 offered by Iventus.
About Sherwood Pharmaceuticals
Sherwood Pharmaceuticals is the result of close interaction with the parents of Cri du Chat children and the entrepreneurial drive and dedication to rare disease patients of our founder, Dr. Malone. We aim to develop the first targeted therapy for Cri du Chat syndrome, to address harmful behavior associated with genetic drivers of this disease. We estimate there are 17k – 18k patients in the 7MM. We can file novel IP for this and related indications, and potentially on route of administration / formulation for these small molecules. We are currently planning the adaptive clinical trial design leveraging a key biomarker to demonstrate pharmacological engagement. This program offers a short path to the market, a long period of exclusivity, and the opportunity to expand the label into broader indications.
Investors Forum
The Investors forum is an exciting opportunity for young life sciences companies that have not reach the series A financing stage and looking for equity capital and/or partnerships. The forum offers excellent opportunities for presenting your company to Venture Capitalists, corporate- and regional investment funds and discuss your business strategy.
If you are interested in participating in the Investors Forum in 2026, please contact Miranda de Regt at miranda.de.regt@dutchlifesciences.com.